|
The world of antibiotics was first introduced in 1940’s.Initially it
was labeled as the “miracle drugs”. With its effectiveness to deal
with bacterial infections it has achieved a secure place in the
medication world. Mupirocin, an ointment used in the treatment of
bacterial infections, more accurately an antibiotic that is used as
a tropical treatment for impetigo. It was on 24th October 2005 that
the Taro Pharmaceutical Industries Ltd announced its approval in USA
from the Food and Drug Administration.
This approval was for the manufacturing of USP, 2% ointment. This
ointment by this industry better known as TARO turns out to be
equivalent to that made by the GlaxoSmithKline’s Bactroban ointment.
Analysis and reports based on the six clinical trails that were
taken to evaluate the effectiveness of mupirocin or the bactroban
showed positive results. It had also been found that those patients
using Mupirocin under the brand name Bactroban cured their problem
up to 905 to 91%.
While those using the same under the brand name Placebo showed
results only up to 7-8 percent. Not only this but also the post
effects of the drugs of both when compared were found to be
astonishing.Bactroban showed that 75% of patients were completely
bacteria free after 3-4 four weeks, this number was outstanding as
compared to just 10% result of Placebo. According to the surveys
conducted it was noticed that mupriocin is an ointment which has an
annual sale of more than $77.00 million in US.
With this pace of the sale it can be predicted that this drug has a
bright future in the antibiotic category.
|
